Literature DB >> 10214961

Anandamide activates human platelets through a pathway independent of the arachidonate cascade.

M Maccarrone1, M Bari, A Menichelli, D Del Principe, A F Agrò.   

Abstract

Anandamide (arachidonoylethanolamide, AnNH) is shown to activate human platelets, a process which was not inhibited by acetylsalicylic acid (aspirin). Unlike AnNH, hydroperoxides generated thereof by lipoxygenase activity, and the congener (13-hydroxy)linoleoylethanolamide, were unable to activate platelets, though they counteracted AnNH-mediated stimulation. On the other hand, palmitoylethanolamide neither activated human platelets nor blocked the AnNH effects. AnNH inactivation by human platelets was afforded by a high-affinity transporter, which was activated by nitric oxide-donors up to 225% of the control. The internalized AnNH could thus be hydrolyzed by a fatty acid amide hydrolase (FAAH), characterized here for the first time.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10214961     DOI: 10.1016/s0014-5793(99)00308-7

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  19 in total

Review 1.  Endocannabinoids and the haematological system.

Authors:  M D Randall
Journal:  Br J Pharmacol       Date:  2007-08-20       Impact factor: 8.739

2.  Acute administration of cannabidiol in vivo suppresses ischaemia-induced cardiac arrhythmias and reduces infarct size when given at reperfusion.

Authors:  Sarah K Walsh; Claire Y Hepburn; Kathleen A Kane; Cherry L Wainwright
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

3.  Characterization of palmitoylethanolamide transport in mouse Neuro-2a neuroblastoma and rat RBL-2H3 basophilic leukaemia cells: comparison with anandamide.

Authors:  S O Jacobsson; C J Fowler
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

4.  2-arachidonyl glycerol activates platelets via conversion to arachidonic acid and not by direct activation of cannabinoid receptors.

Authors:  Oliver P Keown; Timothy J Winterburn; Cherry L Wainwright; Sandra M Macrury; Ilene Neilson; Fiona Barrett; Stephen J Leslie; Ian L Megson
Journal:  Br J Clin Pharmacol       Date:  2010-08       Impact factor: 4.335

Review 5.  Therapeutic potential of cannabinoids in CNS disease.

Authors:  J Ludovic Croxford
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 6.  Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly.

Authors:  Pal Pacher; Sabine Steffens; György Haskó; Thomas H Schindler; George Kunos
Journal:  Nat Rev Cardiol       Date:  2017-09-14       Impact factor: 32.419

7.  Expression of the endocannabinoid system in the bi-potential HEL cell line: commitment to the megakaryoblastic lineage by 2-arachidonoylglycerol.

Authors:  Maria Valeria Catani; Filomena Fezza; Samantha Baldassarri; Valeria Gasperi; Alessandra Bertoni; Nicoletta Pasquariello; Alessandro Finazzi-Agrò; Fabiola Sinigaglia; Luciana Avigliano; Mauro Maccarrone
Journal:  J Mol Med (Berl)       Date:  2008-09-27       Impact factor: 4.599

8.  Anandamide extends platelets survival through CB(1)-dependent Akt signaling.

Authors:  Maria Valeria Catani; Valeria Gasperi; Daniela Evangelista; Alessandro Finazzi Agrò; Luciana Avigliano; Mauro Maccarrone
Journal:  Cell Mol Life Sci       Date:  2009-11-20       Impact factor: 9.261

Review 9.  The emerging role of the endocannabinoid system in cardiovascular disease.

Authors:  Pál Pacher; Sabine Steffens
Journal:  Semin Immunopathol       Date:  2009-04-09       Impact factor: 9.623

Review 10.  Downstream effects of endocannabinoid on blood cells: implications for health and disease.

Authors:  Valeria Gasperi; Daniela Evangelista; Isabella Savini; Domenico Del Principe; Luciana Avigliano; Mauro Maccarrone; Maria Valeria Catani
Journal:  Cell Mol Life Sci       Date:  2015-05-10       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.